Preliminary Report of Expression of <i>bax</i> in Oral Cavity Pathologies

Niedzielska, Iwona; Niedzielski, Z.; Sypniewski, D.; Mazurek, U.; Wilczok, T.; Dąbek, J.

doi:10.14712/fb2006052060190

Fol. Biol. 2006, 52, 190-193

https://doi.org/10.14712/fb2006052060190

Preliminary Report of Expression of bax in Oral Cavity Pathologies

Iwona Niedzielska¹, Z. Niedzielski¹, D. Sypniewski², U. Mazurek², T. Wilczok², J. Dąbek²

¹Department of Maxillofacial Surgery, Medical University of Silesia, Katowice, Poland
²Department of Molecular Biology and Genetics, Medical University of Silesia, Katowice, Poland

Received August 2006
Accepted November 2006

Bax is considered one of major effectors of apoptosis – programmed cell death. Immunohistochemical analysis of in vitro patterns of bax expression was mostly investigated in mammalian cell lines and tissues. The present study is the first in vivo molecular analysis of bax expression in oral cavity pathologies. The study population consisted of 45 patients with hyperplasia, neoplasm in situ malignancy, and carcinoma. Biopsies were taken from incision line, tumour section, and healthy tissue. bax expression was investigated depending on the site of biopsy material sampling and final histopathology result. No statistically significant difference was demonstrated in bax expression between four hyperplasia subgroups. However, statistically significant differences in bax expression were found between the three basic study groups (P = 0.001). Statistically significant differences in bax expression were demonstrated depending on tissue collection site (P = 0.0002). We conclude that differences in bax expression may play a role in the pathogenesis of neoplastic disease.